Pharmaceuticals

What Is The Long-Term Forecast For The Alpha Glucosidase Inhibitors Market Growing At 7.6% CAGR?

September 23, 2025 by Marketing Posting

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Much Will The Alpha Glucosidase Inhibitors Market Be Worth By 2029?#_x000D_

The scale of the alpha glucosidase inhibitors market has significantly expanded in the past couple of years. The market is projected to rise from a worth of $4.52 billion in 2024 to $4.84 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. The expansion during the historical period is due to a surge in diabetes cases, the rise in consciousness about diabetes management, advancements in treatment methodologies for diabetes, preference for orally administered antidiabetic drugs, and the impact of clinical research and evidence-supported medicine._x000D_

_x000D_

Expectations are high for the alpha glucosidase inhibitors market, which is anticipated to experience robust expansion over the coming years. The market is projected to increase to “$6.49 billion in 2029” with a compound annual growth rate (CAGR) of 7.6%. Factors contributing to the growth during this forecast period are an increasing focus on early intervention, a rise in the elderly population, worldwide healthcare initiatives to control diabetes, and inclusion in combination therapy plans. Noteworthy trends for this period include a shift towards patient-focused strategies, emphasis on managing type 2 diabetes, advancements in drug delivery technology, emerging markets and globalization, and an increase in collaborations and partnerships._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=11880&type=smp_x000D_

_x000D_

#What Growth-Enabling Forces Are Impacting The Alpha Glucosidase Inhibitors Market?#_x000D_

The increasing occurrence of diabetes on a global scale is anticipated to boost the expansion of the alpha-glucosidase inhibitors market in the future. Diabetes, characterized by elevated levels of blood sugar or blood glucose over the long term, is a metabolic disorder that can, over time, cause severe damage to the heart, blood vessels, eyes, kidneys, and nerves. Alpha-glucosidase inhibitors obstruct the absorption of carbohydrates in the small intestine, thereby preventing an increase in post-meal blood glucose levels and aiding in diabetes management. As per the Belgium-based International Diabetes Federation, as of November 2022, there were 537 million adults (or 1 in 10) with diabetes worldwide. The global diabetes occurrence is projected to escalate to 643 million people by 2030 and 783 million people by 2045. Consequently, the global surge in diabetes occurrence is propelling the expansion of the alpha-glucosidase inhibitors market._x000D_

_x000D_

#Which Segment Accounts For The Largest Share In The Alpha Glucosidase Inhibitors Market?#_x000D_

The alpha glucosidase inhibitors market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Dumping Syndrome, Type 2 Diabetes_x000D_

2) By Drug Class: Acarbose, Miglitol, Voglibose_x000D_

3) By Constituent: Glucoamylase, Isomaltase, Maltase, Sucrase_x000D_

4) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies_x000D_

_x000D_

Subsegments:_x000D_

1) By Dumping Syndrome: Post-Gastric Surgery Management, Symptomatic Treatment _x000D_

2) By Type 2 Diabetes: Monotherapy, Combination Therapy _x000D_

_x000D_

#Which Long-Term Trends Will Play A Crucial Role In The Alpha Glucosidase Inhibitors Market?#_x000D_

In the alpha-glucosidase inhibitors market, product innovation is emerging as a significant trend. Major enterprises in this market are formulating new products to maintain their competitive edge. An example of this occurred in January 2023 when TheracosBio, a US pharmaceutical firm, obtained approval from the U.S. Food and Drug Administration (FDA) for its product, Brenzavvy (bexagliflozin), designed to treat adults with type 2 diabetes. Brenzavvy, a unique oral suppressant of the sodium-glucose cotransporter 2 (SGLT2), is recommended as an addition to diet and exercise regimes to aid those with type 2 diabetes in effectively controlling their blood sugar levels, as it prompts the kidneys to discharge sugar via urine._x000D_

_x000D_

#Which Organizations Are At The Forefront Of The Alpha Glucosidase Inhibitors Market?#_x000D_

Major companies operating in the alpha glucosidase inhibitors market include Bayer AG, Merck & Co., Alkem Laboratories Ltd., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Emcure Pharmaceuticals Ltd., Lupin Ltd., Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company, Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd., Pfizer Inc., Boehringer Ingelheim International GmbH, AstraZeneca PLC, Mitsubishi Tanabe Pharma Corporation, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb, Teva Pharmaceutical Industries Ltd., Hanmi Pharmaceuticals Co., Ltd., Eisai Co., Ltd., Biocon Limited, Cadila Pharmaceuticals Ltd _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report_x000D_

_x000D_

#Which Region Is Forecasted To Lead The Alpha Glucosidase Inhibitors Market In The Coming Years?#_x000D_

North America was the largest region in the alpha glucosidase inhibitors market in 2024. Middle-East is expected to be the fastest-growing region in the forecast period. The regions covered in the alpha glucosidase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=11880&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_